Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
… patients were included (mean age 58.5±13.2 years; 62.7% male). Tezepelumab was used as first-line in 25/52 (48.1%), second-line in 15/52 (…
…p inhibitors, topical corticosteroids), biologics (particularly dupilumab), and endoscopic dilation for fibrostenotic complications. Evid…
…Objective The approval of budesonide orodispersible tablets and dupilumab has introduced new therapeutic options for the treatment of eos…
…6 patients were on antihistamines or montelukast and 5 received dupilumab. PD-L1 expression was available for 17 patients with a median e…
…umab n=442, dupilumab n=69, mepolizumab n=146, omalizumab n=51, tezepelumab n=69, not recorded n=29. 49.3% of patients were taking maintena…
…0) • Mepolizumab 0 (0) • Benralizumab 1 (9) • Dupilumab 1 (9) • Tezepelumab 6 (55) • None 2 (18) Prior biological therapy use n% 0 4 (36) 1…
… benralizumab, 27.3% to 36.4% for dupilumab, 24.2% to 40.9% for mepolizumab, and 11.1% to 33.3% for omalizumab from Year 1 to Year 3. Basel…
… experienced a dramatic and sustained clinical improvement with infliximab. This case highlights the diagnostic challenges posed by atypic…